You can use your existing Medical Independent, MediLearning or PharmacistCPD account to log in.


Medicalindependent.ie is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.


The benefits of registering: only registered users:
  • receive the ecCopy two days prior to the printed edition.
  • have automatic access to our free CPD sites.
  • can partake in our online MCQs.
  • can enter our online sports quiz.

Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

Download the new Mindo app for both IOS & Android.

  • Get notified when a story goes live
  • Access Premium Content
  • Read Offline
 

You are reading 1 of 2 free-access articles allowed for 30 days

New breast cancer trial opens this week

By Mindo - 29th Jun 2016 | 3 views

It is expected that up to 34 patients will take part in the trial, which will be conducted over the next 2-3 years.

The trials are set to take place in Beaumont Hospital, St Vincent’s University Hospital, St. James’s Hospital, University Hospital Galway and Cork University Hospital at a cost of approximately €750,000.

Cancer Trials Ireland announced that the trial will test for the first time the use of the new drug copanlisib in combination with trastuzumab to treat advanced HER2-positive (HER2+) breast cancer which has progressed or recurred in patients during or following standard anti-HER2 treatment.

The trial is sponsored by Cancer Trials Ireland and supported by Bayer HealthCare AG.

Prof Bryan Hennessy, Clinical Lead, Cancer Trials Ireland said that copanlisib could help to reverse the resistance of some HER2+ breast cancers to trastuzumab (a commonly usedanti-HER2 treatment) and lead to a new therapy for advanced HER2+ breast cancer.

“It is known that HER2+ breast cancer can become resistant to current HER2 therapy,” he said

“We are now learning how this happens. The switching on of a pathway called the PI3K pathway in cancer cells is often responsible. One of the possible ways this happens is through mutations (changes) that occur in a gene called PIK3CA. Research studies that we have carried out at the laboratory level have suggested that blocking the abnormal activity of the PI3K pathway in cancer cells, may help to reverse the resistance of some HER2+ breast cancers to HER2 treatments including trastuzumab.”

To find out more about the trial and their suitability, patients should ask their doctor or healthcare professional. Information on other cancer trials is available at www.cancertrials.ie <http://www.cancertrials.ie> .

Leave a Reply

Latest Issue
The Medical Independent – 24 June 2021

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read